BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14628398)

  • 1. Patient selection in the ESRD managed care demonstration.
    Shapiro JR; Dykstra DM; Pisoni R; Beronja N; Gaylin DS; Oppenheimer CC; Rubin RJ; Held PJ
    Health Care Financ Rev; 2003; 24(4):31-43. PubMed ID: 14628398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESRD managed care demonstration: financial implications.
    Dykstra DM; Beronja N; Menges J; Gaylin DS; Oppenheimer CC; Shapiro JR; Wolfe RA; Rubin RJ; Held PJ
    Health Care Financ Rev; 2003; 24(4):59-75. PubMed ID: 14628400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the ESRD managed care demonstration operations.
    Oppenheimer CC; Shapiro JR; Beronja N; Dykstra DM; Gaylin DS; Held PJ; Rubin RJ
    Health Care Financ Rev; 2003; 24(4):7-29. PubMed ID: 14628397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and patient satisfaction: ESRD managed care demonstration.
    Pifer TB; Bragg-Gresham JL; Dykstra DM; Shapiro JR; Oppenheimer CC; Gaylin DS; Beronja N; Rubin RJ; Held PJ
    Health Care Financ Rev; 2003; 24(4):45-58. PubMed ID: 14628399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. End stage renal disease and Medicare.
    Greer JW
    Health Care Financ Rev; 2003; 24(4):1-5. PubMed ID: 14628396
    [No Abstract]   [Full Text] [Related]  

  • 6. Selection experiences in Medicare HMOs: pre-enrollment expenditures.
    Call KT; Dowd B; Feldman R; Maciejewski M
    Health Care Financ Rev; 1999; 20(4):197-209. PubMed ID: 11482122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an end-stage renal disease managed care demonstration.
    Cooper BS; Eggers PW; Edington BM
    Adv Ren Replace Ther; 1997 Oct; 4(4):332-9. PubMed ID: 9356685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare HMOs reveal unique contracting strategies for new ESRD risk demonstration.
    Public Sect Contract Rep; 1997 May; 3(5):74-6. PubMed ID: 10174874
    [No Abstract]   [Full Text] [Related]  

  • 9. Disenrollment from Medicare HMOs.
    Call KT; Dowd BE; Feldman R; Lurie N; McBean MA; Maciejewski M
    Am J Manag Care; 2001 Jan; 7(1):37-51. PubMed ID: 11209449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of HMOs on the inpatient utilization of medicare beneficiaries.
    Dhanani N; O'Leary JF; Keeler E; Bamezai A; Melnick G
    Health Serv Res; 2004 Oct; 39(5):1607-27. PubMed ID: 15333125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participants, analysts share preliminary data from the ESRD managed care demonstration project.
    Neumann ME
    Nephrol News Issues; 2001 Jul; 15(8):15-6. PubMed ID: 12099225
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of the Comprehensive End-Stage Renal Disease Care Model With Medicare Payments and Quality of Care for Beneficiaries With End-Stage Renal Disease.
    Marrufo G; Colligan EM; Negrusa B; Ullman D; Messana J; Shah A; Duvall T; Hirth RA
    JAMA Intern Med; 2020 Jun; 180(6):852-860. PubMed ID: 32227133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncle Sam doesn't overcompensate Medicare risk HMOs, survey says.
    Health Care Strateg Manage; 1996 Jul; 14(7):6-7. PubMed ID: 10158470
    [No Abstract]   [Full Text] [Related]  

  • 14. Service-level selection by HMOs in Medicare.
    Cao Z; McGuire TG
    J Health Econ; 2003 Nov; 22(6):915-31. PubMed ID: 14604553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of inpatient severity, average length of stay, and cost for traditional fee-for-service medicare and medicare HMOs in Florida.
    Revere L; Large J; Langland-Orban B
    Health Care Manage Rev; 2004; 29(4):320-8. PubMed ID: 15600110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Medicare-HMO revolving door--the healthy go in and the sick go out.
    Morgan RO; Virnig BA; DeVito CA; Persily NA
    N Engl J Med; 1997 Jul; 337(3):169-75. PubMed ID: 9219704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing mortality and time until death for medicare HMO and FFS beneficiaries.
    Maciejewski ML; Dowd B; Call KT; Feldman R
    Health Serv Res; 2001 Feb; 35(6):1245-65. PubMed ID: 11221818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health plan choice in the Twin Cities Medicare market.
    Dowd B; Moscovice I; Feldman R; Finch M; Wisner C; Hillson S
    Med Care; 1994 Oct; 32(10):1019-39. PubMed ID: 7934269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does managed care manage the frail elderly? The case of hospital readmissions in fee-for-service versus HMO systems.
    Experton B; Ozminkowski RJ; Pearlman DN; Li Z; Thompson S
    Am J Prev Med; 1999 Apr; 16(3):163-72. PubMed ID: 10198653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of preventive care services, beneficiary characteristics, and Medicare HMO performance.
    Greene J; Blustein J; Laflamme KA
    Health Care Financ Rev; 2001; 22(4):141-53. PubMed ID: 12378763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.